News Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion Please read the announcement in PDF Attachment 2023_Chinese_merger_approval_granted Related Continue Reading Previous Japan awaits home heroes TOYOTA GAZOO RacingNext Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion Related Stories News SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance News Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference News MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury News Faraday Future to Host Investor Presentation Webcast News Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer News Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
